TITLE

Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement

AUTHOR(S)
Okroj, Marcin; Eriksson, Ingrid; Österborg, Anders; Blom, Anna M.
PUB. DATE
December 2013
SOURCE
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
92576479

 

Related Articles

  • Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia. Chuda, Ravindra R.; Vishnu, Prakash; Aboulafia, David // Current Drug Therapy;Dec2012, Vol. 7 Issue 4, p281 

    Chronic lymphocytic leukemia (CLL) is a heterogeneous disease arising from monoclonal proliferation of B lymphocytes. In the absence of poor risk features, CLL is characterized by an indolent clinical course but in 2012 it is still considered an incurable malignancy. Treatment of CLL is highly...

  • Rituximab.  // Reactions Weekly;Oct2014, Vol. 1521 Issue 1, p144 

    An abstract of the article "Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression," by K. Shimada and colleagues is presented.

  • Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity. Lin Wu; Sanbao Su; Fengming Liu; Tao Xu; Xiaoxiao Wang; Yan Huang; Xinlu Sun; Xiaowen Ge; Ting Chen; Huixia Liu; Chun Wang; Chorev, Michael; Ting Xu; Xuebin Qin // Current Pharmaceutical Design;Sep2012, Vol. 18 Issue 26, p4187 

    Complement dependent cytotoxicity (CDC) significantly contributes to Rituximab (RTX) and Ofatumumab (OFA) efficacies in the treatment of B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Human CD59 (hCD59) is a key complement regulatory protein that restricts the...

  • Ofatumumab Injection.  // AHFS Consumer Medication Information;Jan2020, p1 

    Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells) in adults who have not gotten better after treatment with fludarabine (Fludara) and alemtuzumab (Campath). Ofatumumab injection is in a class of medications called monoclonal...

  • Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Middleton, O; Cosimo, E; Dobbin, E; McCaig, A M; Clarke, C; Brant, A M; Leach, M T; Michie, A M; Wheadon, H // Leukemia (08876924);Jan2015, Vol. 29 Issue 1, p107 

    Monoclonal antibodies (MAbs) form a central part of chronic lymphocytic leukaemia (CLL) treatment. We therefore evaluated whether complement defects in CLL patients reduced the induction of complement-dependent cytotoxicity (CDC) by using anti-CD20 MAbs rituximab (RTX) and ofatumumab (OFA)....

  • Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Stanglmaier, Michael; Reis, Simone; Hallek, Michael // Annals of Hematology;Oct2004, Vol. 83 Issue 10, p634 

    The monoclonal antibodies (MoAbs) alemtuzumab (anti-CD52) and rituximab (anti-CD20) produce objective clinical responses in patients with chronic lymphocytic leukemia (CLL). However, their mechanisms of action are not fully understood. Therefore, we investigated the mechanisms of lymphoma and...

  • Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Baer II, William H.; Maini, Archana; Jacobs, Ira // Pharmaceuticals;May2014, Vol. 7 Issue 5, p530 

    Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources. This study examined access to rituximab and identified potential barriers to its use in the United States, Mexico,...

  • Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Baer II, William H.; Maini, Archana; Jacobs, Ira // Pharmaceuticals;Sep2014, Vol. 7 Issue 9, p530 

    Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources. This study examined access to rituximab and identified potential barriers to its use in the United States, Mexico,...

  • New developments in the management of chronic lymphocytic leukemia: role of ofatumumab. Laurenti, Luca; Innocenti, Idanna; Autore, Francesco; Sica, Simona; Efremov, Dimitar G. // OncoTargets & Therapy;Jan2016, Vol. 9, p421 

    Ofatumumab is one of the three anti-CD20 monoclonal antibodies currently available for the treatment of chronic lymphocytic leukemia (CLL). The US Food and Drug Administration (FDA) approved the use of ofatumumab in patients with CLL refractory to fludarabine and alemtuzumab in 2009, and the...

  • Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Hörl, S; Bánki, Z; Huber, G; Ejaz, A; Windisch, D; Muellauer, B; Willenbacher, E; Steurer, M; Stoiber, H // Leukemia (08876924);Nov2013, Vol. 27 Issue 11, p2268 

    A correction to the article "Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity" by D. Windisch and B. Muellauer that was published in the previous issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics